RxDoctor Payments Data

Sara Springer

Nurse Practitioner · Old Monroe, MONPI 1104186345

Payments from drug & device makers

$2,401in general payments, 2019–2025

Across 105 payments — averaging $22.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$288
  • GSK$253
  • Jazz Pharmaceuticals Inc.$204
  • Boehringer Ingelheim$158
  • Medtronic$134
  • Daiichi Sankyo Inc.$125
  • plus $1K from 23 others

What the payments were for

  • Food & beverage$2,396100%
  • Education$60%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,401 in reported general payments places this provider in the 85th percentile of 1,898 nurse practitioner providers in Missouri.

See all nurse practitioner providers in Missouri

Medicare billing

Part B allowed, 2024
$4,237
Medicare patients
28
Services billed
49

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol167$143,611
JardianceEmpagliflozin139$122,630
VelphoroSucroferric Oxyhydroxide20$107,526
VeltassaPatiromer Calcium Sorbitex49$36,244
KerendiaFinerenone12$10,378
Sevelamer Carbonate43$6,032
Cinacalcet Hcl15$5,940
Nebivolol Hcl50$4,152
Clonidine15$3,184
Febuxostat17$3,170
Torsemide91$2,370
Furosemide410$2,296
Calcium Acetate16$1,736
Hydralazine Hcl124$1,730
Amlodipine Besylate288$1,614

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$288$143,611167 claims
Boehringer IngelheimJardiance$158$122,630139 claims
Fresenius USA Marketing, Inc.Velphoro$101$107,52620 claims
BayerKerendia$121$10,37812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,898 nurse practitioner providers in Missouri.

Other nurse practitioner in Old Monroe

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →